An amiloride derivative is active against the F1Fo-ATP synthase and cytochrome bd oxidase of Mycobacterium tuberculosis
出版年份 2022 全文链接
标题
An amiloride derivative is active against the F1Fo-ATP synthase and cytochrome bd oxidase of Mycobacterium tuberculosis
作者
关键词
-
出版物
Communications Biology
Volume 5, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-02-24
DOI
10.1038/s42003-022-03110-8
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The cryo-EM structure of the bd oxidase from M. tuberculosis reveals a unique structural framework and enables rational drug design to combat TB
- (2021) Schara Safarian et al. Nature Communications
- Dual inhibition of the terminal oxidases eradicates antibiotic‐tolerant Mycobacterium tuberculosis
- (2020) Bei Shi Lee et al. EMBO Molecular Medicine
- Structure of mycobacterial ATP synthase bound to the tuberculosis drug bedaquiline
- (2020) Hui Guo et al. NATURE
- Utilization of CRISPR Interference To Validate MmpL3 as a Drug Target in Mycobacterium tuberculosis
- (2019) Matthew B. McNeil et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Mode-of-action profiling reveals glutamine synthetase as a collateral metabolic vulnerability of M. tuberculosis to bedaquiline
- (2019) Zhe Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- 6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease
- (2019) Benjamin J. Buckley et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Targeting bacterial energetics to produce new antimicrobials
- (2018) Kiel Hards et al. DRUG RESISTANCE UPDATES
- Ionophoric effects of the antitubercular drug bedaquiline
- (2018) Kiel Hards et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- 6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer
- (2018) Benjamin J. Buckley et al. JOURNAL OF MEDICINAL CHEMISTRY
- Pyrazolo[1,5-a]pyridine Inhibitor of the Respiratory Cytochrome bcc Complex for the Treatment of Drug-Resistant Tuberculosis
- (2018) Xiaoyun Lu et al. ACS Infectious Diseases
- Discovery of Imidazo[1,2-a]pyridine Ethers and Squaramides as Selective and Potent Inhibitors of Mycobacterial Adenosine Triphosphate (ATP) Synthesis
- (2017) Subramanyam J. Tantry et al. JOURNAL OF MEDICINAL CHEMISTRY
- Exploiting the synthetic lethality between terminal respiratory oxidases to killMycobacterium tuberculosisand clear host infection
- (2017) Nitin P. Kalia et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Turning the respiratory flexibility of Mycobacterium tuberculosis against itself
- (2016) Dirk A. Lamprecht et al. Nature Communications
- Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis
- (2015) Supriya Singh et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Bactericidal mode of action of bedaquiline
- (2015) K. Hards et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Antiinfectives targeting enzymes and the proton motive force
- (2015) Xinxin Feng et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Structure of the mycobacterial ATP synthase Fo rotor ring in complex with the anti-TB drug bedaquiline
- (2015) L. Preiss et al. Science Advances
- Cross-Resistance between Clofazimine and Bedaquiline through Upregulation of MmpL5 in Mycobacterium tuberculosis
- (2014) R. C. Hartkoorn et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- X-Ray Structure of Acid-Sensing Ion Channel 1–Snake Toxin Complex Reveals Open State of a Na+-Selective Channel
- (2014) Isabelle Baconguis et al. CELL
- Multitarget Drug Discovery for Tuberculosis and Other Infectious Diseases
- (2014) Kai Li et al. JOURNAL OF MEDICINAL CHEMISTRY
- Acquired Resistance of Mycobacterium tuberculosis to Bedaquiline
- (2014) Koen Andries et al. PLoS One
- Enhanced Specialized Transduction Using Recombineering in Mycobacterium tuberculosis
- (2014) J. M. Tufariello et al. mBio
- Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism
- (2014) Anil Koul et al. Nature Communications
- Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis
- (2014) Keertan Dheda et al. Lancet Respiratory Medicine
- Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis
- (2013) Kevin Pethe et al. NATURE MEDICINE
- Tuberculosis success
- (2013) Dan Jones NATURE REVIEWS DRUG DISCOVERY
- Multifunctional essentiality of succinate metabolism in adaptation to hypoxia in Mycobacterium tuberculosis
- (2013) H. Eoh et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Approval of Novel TB Drug Celebrated--With Restraint
- (2013) J. Cohen SCIENCE
- Randomized Pilot Trial of Eight Weeks of Bedaquiline (TMC207) Treatment for Multidrug-Resistant Tuberculosis: Long-Term Outcome, Tolerability, and Effect on Emergence of Drug Resistance
- (2012) A. H. Diacon et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Regulation of proline metabolism in mycobacteria and its role in carbon metabolism under hypoxia
- (2012) Michael Berney et al. MOLECULAR MICROBIOLOGY
- Avogadro: an advanced semantic chemical editor, visualization, and analysis platform
- (2012) Marcus D Hanwell et al. Journal of Cheminformatics
- In vitro differentiation of human macrophages with enhanced antimycobacterial activity
- (2011) Guillaume Vogt et al. JOURNAL OF CLINICAL INVESTIGATION
- Central carbon metabolism in Mycobacterium tuberculosis: an unexpected frontier
- (2011) Kyu Y. Rhee et al. TRENDS IN MICROBIOLOGY
- The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis
- (2009) Andreas H. Diacon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Diarylquinolines Are Bactericidal for Dormant Mycobacteria as a Result of Disturbed ATP Homeostasis
- (2008) Anil Koul et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started